Opportunistic Intestinal Protozoan Infections and Immunological Status of HIV/AIDS Patients in Jalingo Local Government, Taraba State
American Journal of Laboratory Medicine
Volume 5, Issue 5, September 2020, Pages: 139-143
Received: Jul. 18, 2020;
Accepted: Aug. 19, 2020;
Published: Sep. 21, 2020
Views 223 Downloads 56
Elkanah Obadiah Sambo, Department of Biological Sciences, Taraba State University, Jalingo, Nigeria
Onyeuku Okechukwu Chinwe, Department of Laboratory Services, Taraba State Specialist Hospital, Jalingo, Nigeria
Obiorah Sylvester Chibuzor, Department of Laboratory Services, Federal Medical Centre, Jalingo, Nigeria
Elkanah Deborah Sambo, Department of Biological Sciences, Taraba State University, Jalingo, Nigeria
Egeonu Stephen Ugoeze, Department of Laboratory Services, Federal Medical Centre, Jalingo, Nigeria
The Human Immunodeficiency Virus (HIV) is a virus that attacks the immune system. Opportunistic intestinal protozoans are among the major contributors to the global intestinal parasite load. This study investigated the danger and complication due to intestinal protozoans’ infection among HIV/AIDS patients in Jalingo metropolis. The study also compared the prevalence of opportunistic intestinal protozoa infection and CD4+ T-Cell count between HIV/AIDS and non HIV patients. The procedure of wet mount technique and faecal concentration methods were employed. The CD4+ count of patients were determined using the Partee Cyflow Counter, which determines the percentage of CD4+ cells of individuals. The prevalence of opportunic intestinal protozoan parasites was higher among female positives, 68 (l9.60%) than the male, 50 (16.50%) with no significant difference (p>0.05). The infection based on age groups revealed that the age group 10-15 years had the highest prevalence of 27 (48.21%) while the age group 41-45 years had the least prevalence of 2 (2.63%). The prevalence of intestinal parasites was highly significant among the study participants with CD4+ count <200 cells/μl. Cryptosporidium spp was significantly associated with HIV positive subjects who had CD4+ count of less than 200 cell/μl. The prevalence of intestinal parasites was highly significant among the study participants with CD4+ count <200 cells/ul. The implications of these findings are discussed and solution proposed to curb opportunistic infections among HIV/AIDS patients.
Elkanah Obadiah Sambo,
Onyeuku Okechukwu Chinwe,
Obiorah Sylvester Chibuzor,
Elkanah Deborah Sambo,
Egeonu Stephen Ugoeze,
Opportunistic Intestinal Protozoan Infections and Immunological Status of HIV/AIDS Patients in Jalingo Local Government, Taraba State, American Journal of Laboratory Medicine.
Vol. 5, No. 5,
2020, pp. 139-143.
Gupta, K., Bala, M., Deb, M., Muralidhar, S. and Sharma Prevalence of intestinal parasitic infections in HIV-infected individuals and their relationship with immune status. Indian Journal of Medical Microbiology, 2013; 31: 161-165.
National Agency for the Control of AIDS. Report on prevalence of HIV/AIDS in Nigeria-National Agency For The Control of HIV/AIDS, 2015; Pg 1129-1178.
Sparks, H., Nair, G., Castellanos-Gonzalez, A., White, A. C. Jr. Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward. Curr Trop Med Rep 2015; 2: 181.
Cheesbrough M. District laboratory practice in tropical countries. New York-Cambridge Press. Part 1, 2nd Edition, 2012; 249-258.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infections. Recommendation for Public Health approach, 2016; 2. 236-287.
Akinsegun, A., Olusola, D. A., Sarah, J. O., Olajumoke, O., Adewumi, A., Majeed, O. and Kingsley, A. Quality of sleep in an HIV population on antiretroviral therapy at an urban tertiary centre in Lagos, Nigeria. Neurology Research International, 2015; 18: 1014-1020.
Obateru, O. A., Bojuwoye, B. J., Olokoba, A. B., Fadeyi, A. F., Olokoba, L. B. Prevalence of intestinal parasites in newly diagnosed HIV/AIDS patients in Ilorin, Nigeria. Alexandria Journal of Medicine, 2017; 53 (2): 111-116
Bokore A, Korme B, Bayisa G. Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study. BMC Pharmacol Toxicol 2018; 19 (1): 28.
Gebretsadik D, Haileslasie H, Feleke DG. Intestinal parasitosis among HIV/AIDS patients who are on anti-retroviral therapy in Kombolcha, North Central, Ethiopia: a cross-sectional study. BMC Res Notes. 2018; 11 (1): 613. doi: 10.1186/s13104-018-3726-6.
Wilcox, C. M. Evaluation of the HIV-infected patient with diarrhea. Update, 2018.
Alemu G, Alelign D, Abossie A. Prevalence of Opportunistic Intestinal Parasites and Associated Factors among HIV Patients while Receiving ART at Arba Minch Hospital in Southern Ethiopia: A Cross-sectional Study. Ethiop J Health Sci. 2018; 28 (2): 147-156. doi: 10.4314/ejhs.v28i2.6
Barcelos Natane Barbosa, Silva Lorena de Freitas e, Dias Regyane Ferreira Guimarães, Menezes Filho Hélio Ranes de, Rodrigues Rosângela Maria. Opportunistic and non-opportunistic intestinal parasites in HIV/ AIDS patients in relation to their clinical and epidemiological status in a specialized medical service in Goiás, Brazil. Rev. Inst. Med. trop. S. Paulo [Internet]. 2018 [cited 2020 Aug 18]; 60: e13. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652018005000206&lng=en. Epub Mar 08, 2018. https://doi.org/10.1590/s1678-9946201860013.
Akinbo F O, Anate P J, Akinbo D B, Omoregie R, Okoosi S, Abdulsalami A, Isah B. Risk factors of intestinal parasitic infections among human immunodeficiency virus-infected patients on highly active antiretroviral therapy. Port Harcourt Med J, 2017; 11: 15-20.
Tiwari, B. R., Ghimire P., Malla, S., Sharma, B. and Karki, S. Intestinal parasitic infection among the HIV-infected patients in Nepal. Journal of Infection in Developing Countries, 2013; 7 (07): 550-5555.
Teklay, G., Haftom, K., Abebaw, A. G. Intestinal parasites among HIV/AIDS patients attending University of Gondar Hospital, northwest Ethiopia. Ethiop. J. Health Dev. 2019; 33 (2): 64-72.